SPRR2A enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity

BMC Molecular Biology

Volumn 13, Issue , 2012, Pages

  Mizuguchi, Yoshiaki ^a   Specht, Susan ^a   Lunz III, John G ^a   Isse, Kumiko ^a   Corbitt, Natasha ^a   Takizawa, Toshihiro ^b   Demetris, Anthony J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; E1A ASSOCIATED P300 PROTEIN; HISTONE DEACETYLASE 1; MESSENGER RNA; PROLINE RICH PROTEIN; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SMALL PROLINE RICH PROTEIN 2A; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CARCINOMA CELL; COMPLEX FORMATION; CONTROLLED STUDY; DEACETYLATION; ENVIRONMENTAL STRESS; GENE EXPRESSION; HUMAN; HUMAN CELL; MEDIATOR; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UBIQUITINATION; WOUND HEALING;

ACETYLATION; CELL LINE, TUMOR; CORNIFIED ENVELOPE PROLINE-RICH PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; DOWN-REGULATION; E1A-ASSOCIATED P300 PROTEIN; HEP G2 CELLS; HISTONE DEACETYLASE 1; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UP-REGULATION;

EID: 84862633786     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-13-20     Document Type: Article

References (39)

1. ElDeiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1((1):45-49.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88(3):323-331. 10.1016/S0092-8674(00)81871-1, 9039259.
3. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009, 137(4):609-622. 10.1016/j.cell.2009.04.050, 19450511.
4. Kruse JP, Gu W. SnapShot: p53 posttranslational modifications. Cell 2008, 133(5):930-930 e931. 10.1016/j.cell.2008.05.020, 18510935.
5. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 2009, 1(6):a000950. 10.1101/cshperspect.a000950, 2882125, 20457558.
6. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001, 20(6):1331-1340. 10.1093/emboj/20.6.1331, 145533, 11250899.
7. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002, 21(22):6236-6245. 10.1093/emboj/cdf616, 137207, 12426395.
8. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458(7242):1127-1130. 10.1038/nature07986, 2814168, 19407794.
9. Arbely E, Natan E, Brandt T, Allen MD, Veprintsev DB, Robinson CV, Chin JW, Joerger AC, Fersht AR. Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc Natl Acad Sci U S A 108(20):8251-8256.
10. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998, 12(18):2831-2841. 10.1101/gad.12.18.2831, 317174, 9744860.
11. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2008, 208(5):875-883.
12. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
13. Cabral A, Voskamp P, Cleton-Jansen AM, South A, Nizetic D, Backendorf C. Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. J Biol Chem 2001, 276(22):19231-19237. 10.1074/jbc.M100336200, 11279051.
14. Patel S, Kartasova T, Segre JA. Mouse Sprr locus: a tandem array of coordinately regulated genes. Mamm Genome 2003, 14(2):140-148. 10.1007/s00335-002-2205-4, 12584609.
15. Demetris AJ, Specht S, Nozaki I, Lunz JG, Stolz DB, Murase N, Wu T. Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial-mesenchymal transition (EMT) in cholangiocytes. J Hepatol 2008, 48(2):276-288. 10.1016/j.jhep.2007.09.019, 2263141, 18155796.
16. Li X, Mohan S, Gu W, Baylink DJ. Analysis of gene expression in the wound repair/regeneration process. Mamm Genome 2001, 12(1):52-59. 10.1007/s003350010230, 11178744.
17. Vermeij WP, Alia A, Backendorf C. ROS quenching potential of the epidermal cornified cell envelope. J Invest Dermatol 131(7):1435-1441.
18. Vermeij WP, Backendorf C. Skin cornification proteins provide global link between ROS detoxification and cell migration during wound healing. PLoS One 5(8):e11957.
19. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A 2009, 106(38):16275-16280. 10.1073/pnas.0904305106, 2752525, 19805293.
20. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, Ozturk M. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 1993, 7(14):1407-1413.
21. Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O, Lacroix M, Le Cam L, Coux O, Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 2007, 9(3):331-338. 10.1038/ncb1545, 17293853.
22. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003, 300(5617):342-344. 10.1126/science.1080386, 12690203.
23. ElDeiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4):817-825. 10.1016/0092-8674(93)90500-P, 8242752.
24. Chai YL, Cui J, Shao N, Shyam E, Reddy P, Rao VN. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 1999, 18(1):263-268. 10.1038/sj.onc.1202323, 9926942.
25. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM, Livingston DM. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998, 2(4):405-415. 10.1016/S1097-2765(00)80140-9, 9809062.
26. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994, 8(8):869-884. 10.1101/gad.8.8.869, 7523245.
27. Eckner R, Ludlow JW, Lill NL, Oldread E, Arany Z, Modjtahedi N, DeCaprio JA, Livingston DM, Morgan JA. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996, 16(7):3454-3464. 231340, 8668161.
28. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382(6589):319-324. 10.1038/382319a0, 8684459.
29. Dornan D, Shimizu H, Burch L, Smith AJ, Hupp TR. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol 2003, 23(23):8846-8861. 10.1128/MCB.23.23.8846-8861.2003, 262654, 14612423.
30. Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011, 129383.
31. Simone C, Stiegler P, Forcales SV, Bagella L, De Luca A, Sartorelli V, Giordano A, Puri PL. Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene 2004, 23(12):2177-2187. 10.1038/sj.onc.1207327, 14968110.
32. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999, 13(19):2490-2501. 10.1101/gad.13.19.2490, 317076, 10521394.
33. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 2003, 23(8):2669-2679. 10.1128/MCB.23.8.2669-2679.2003, 152549, 12665570.
34. Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X, Shu G, Song J. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol 42(9):1489-1497.
35. Vaziri H, Dessain SK. Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107(2):149-159. 10.1016/S0092-8674(01)00527-X, 11672523.
36. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006, 6(12):909-923. 10.1038/nrc2012, 17128209.
37. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition. J Biol Chem 2004, 279(43):44344-44354. 10.1074/jbc.M404852200, 15294900.
38. Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massague J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 2000, 100(2):229-240. 10.1016/S0092-8674(00)81561-5, 10660046.
39. Nozaki I, Lunz JG, Specht S, Stolz DB, Taguchi K, Subbotin VM, Murase N, Demetris AJ. Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest 2005, 85(1):109-123.